Functional role for cannabinoids in respiratory stability during sleep.

  title={Functional role for cannabinoids in respiratory stability during sleep.},
  author={David W. Carley and Sasa Paviovic and Marina Janelidze and Miodrag G. Radulovacki},
  volume={25 4},
STUDY OBJECTIVES Serotonin, acting in the peripheral nervous system, can exacerbate sleep-related apnea, and systemically administered serotonin antagonists reduce sleep-disordered respiration in rats and bulldogs. Because cannabinoid receptor agonists are known to inhibit the excitatory effects of serotonin on nodose ganglion cells, we examined the effects of endogenous (oleamide) and exogenous (delta9-tetrahydrocannabinol; delta9THC) cannabimimetic agents on sleep-related apnea. DESIGN… 

Figures and Tables from this paper

Effects of Cannabinoid Agonists and Antagonists on Sleep and Breathing in Sprague-Dawley Rats

Dronabinol's effects on apneas were dependent on CB1 receptor activation, while dronabinols effects on REM sleep were CB receptor-independent, according to a natural model of central sleep apnea.

Intranodose ganglion injections of dronabinol attenuate serotonin-induced apnea in Sprague-Dawley rat

Proof of Concept Trial of Dronabinol in Obstructive Sleep Apnea

Dronabinol treatment is safe and well-tolerated in OSA patients at doses of 2.5–10 mg daily and significantly reduces AHI in the short-term and should be confirmed in a larger study in order to identify sub-populations with OSA that may benefit from cannabimimetic pharmacologic therapy.

Anandamide enhances extracellular levels of adenosine and induces sleep: an in vivo microdialysis study.

Anandamide increased adenosine levels in the basal forebrain and also increased sleep in conditions where sleep may be severely attenuated, and this findings identify a potential therapeutic use of endocannabinoids to induce sleep in terms of dosage and mechanism.

Intracerebroventricular injections of dronabinol, a cannabinoid receptor agonist, does not attenuate serotonin-induced apnea in Sprague-Dawley rats

The data show that ICV injection of dronabinol did not decrease 5-HT-induced apneas, and did not increase genioglossus activity, and this in contrast to published results of dRONabinol’s effect on apnea via the vagus nerve.

Effects of Cannabinoid Agonists and Antagonists on Sleep in Laboratory Animals.

In this chapter, the studies detailing the effects of cannabinoids on sleep in laboratory animals are reviewed and some evidence suggests that some sleep effects may be elicited via non-cannabinoid receptor-dependent mechanisms.

DMSO potentiates the suppressive effect of dronabinol, a cannabinoid, on sleep apnea and REM sleep

Dronabinol in 25% DMSO partially potentiated dronabinl’s effects, suggesting a concomitant biological effect of D MSO on breathing during sleep.

Clinical Management of Sleep and Sleep Disorders With Cannabis and Cannabinoids: Implications to Practicing Psychiatrists

Preclinical investigations have demonstrated that combining the agent oleamide and THC aids in the stabilization of respiration in all stages of sleep as well as the maintenance of autonomic stability during sleep.

Cannabinoid Type 1 and Type 2 Receptor Antagonists Prevent Attenuation of Serotonin-Induced Reflex Apneas by Dronabinol in Sprague-Dawley Rats

Dronabinol injections into nodose ganglia of the CB1, CB2, and combined CB1/CB2 groups did not attenuate 5-HT-induced reflex apnea duration, and CB1 and CB2 antagonists had no effect on dronabinl’s ability to increase phasic EMGgg.



Role of peripheral serotonin in the regulation of central sleep apneas in rats.

It is concluded that binding at 5-HT3 receptors in the peripheral nervous system promotes REM-related apnea genesis in rats and suggests that endogenous 5-ht, acting at least at peripheral 5- HT3 receptors, may play a baseline physiologic role in the expression of spontaneous central apneas in rats.

Serotonin 5-HT3-receptor antagonist GR 38032F suppresses sleep apneas in rats.

The authors' data implicate 5-HT3 receptor systems in determining sleep-related respiratory drive and apnea expression in rats, effects which are most probably mediated by vagal afferents.

The effects of ondansetron on sleep-disordered breathing in the English bulldog.

Ondansetron had no effect on either sleep efficiency or sleep architecture, and there were no effects on either oxyhemoglobin saturation nadirs or on the sleep time with saturations <90%.

Mirtazapine, a mixed-profile serotonin agonist/antagonist, suppresses sleep apnea in the rat.

It is concluded that mirtazapine, over a 50-fold dose range, significantly reduces central apnea expression during NREM and REM sleep in the rat and that the efficacy of this compound to suppress apnea in all sleep stages most probably arises from its mixed agonist/antagonist profile at serotonin receptors.

Effect of serotonin uptake inhibition on breathing during sleep and daytime symptoms in obstructive sleep apnea.

It is concluded that enhanced serotonergic transmission improves breathing during NREM sleep in OSA, and this effect is poorly related to effects on sleep architecture or daytime symptoms.

The effects of trazodone with L-tryptophan on sleep-disordered breathing in the English bulldog.

Trazodone with L-tryptophan can treat sleep-disordered breathing (SDB) in an animal model of OSAHS; the effectiveness of this therapy may be related to increased upper airway dilator activity in sleep and/or enhanced slow-wave sleep.

The hypnotic actions of oleamide are blocked by a cannabinoid receptor antagonist.

Data suggest that at least one aspect of the hypnotic action of OA involves interactions with the CB1 receptor system, possibly by blocking the metabolism of the endogenous CB1 cannabinoid-1 receptor agonist anandamide.

Brain lipids that induce sleep are novel modulators of 5-hydroxytrypamine receptors.

Modulation of 5-HT2 receptors by ODA and related lipids may represent a novel mechanism for regulation of receptors that activate G proteins and thereby play a role in alertness, sleep, and mood as well as disturbances of these states.

L-tryptophan in the treatment of impaired respiration in sleep.

  • H. Schmidt
  • Biology, Medicine
    Bulletin europeen de physiopathologie respiratoire
  • 1983
Serotoninergic activity with a defect in feedback control of tryptophan-serotonin metabolism is postulated as a potential mechanism in the pathophysiology of obstructive sleep apnea and the enhanced usefulness of L-T in combination with protriptyline is predicted.